We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bruker Grows on NMR & Nano Businesses amid Several Odds
Read MoreHide Full Article
On Jun 6, we issued an updated research report on Billerica, MA-based Bruker Corporation (BRKR - Free Report) , a manufacturer of proprietary life science and materials research systems.
For quite sometime, Bruker has been witnessing growth in its Nano Surfaces business on restructuring and cost reduction actions. The portfolio also got a boost from the acquisition of Hysitron nano indenting products in the beginning of 2017. Additionally, the company gained traction in the semiconductor metrology markets and in certain industrial and applied end-market segments.
We are encouraged by Bruker’s latest product developmental activities under the Nuclear Magnetic Resonance (NMR) spectroscopy business. The company’s latest line of launches includes the AVANCE NEO platform, a next-generation NMR console and S8 TIGER Series 2 spectrometer. Management has also claimed to have made technical and quality progress with its high temperature superconducting (HTS) tapes. Currently, management expects HTS to boost its ultra-high field 1.2 gigahertz NMR business in 2018 and beyond. The market is also upbeat about Bruker’s new revolutionary approach for the analysis of microorganisms – MALDI Biotyper.
Over the recent past, Bruker has planned strategies to improve its financial performance. These initiatives include the divestiture of certain non-core businesses, outsourcing of various manufacturing activities and transferring or ceasing of operations at certain facilities. Meanwhile, the company’s raised revenue guidance raises optimism.
On the flip side, over the last three months, the company is trading below the Zacks categorized Instruments - Scientific industry. During this period, the stock has generated a return of 17.0%, below the 18.2% gain of the broader industry. We believe the underperformance is due to Bruker’s weak organic revenue performance.
Bruker conducts 80% of its business in international markets. As a result, adverse currency fluctuations continue to result in losses at the company. In 2017, changes in foreign currency rates are expected to have an adverse impact of 2.5% on revenues. In addition, currency fluctuations could make the price of Bruker’s products less competitive than that of its principal competitors' offerings. Moreover, headwinds such as unfavorable economic conditions and competitive threats continue to raise concerns.
Zacks Rank & Key Picks
Bruker currently carries Zacks Rank #3 (Hold). A few better-ranked medical stocks are Align Technology, Inc. (ALGN - Free Report) , Inogen, Inc. (INGN - Free Report) and Accelerate Diagnostics, Inc. (AXDX - Free Report) . Notably, Align Technologyand Inogen sport a Zacks Rank #1 (Strong Buy), while Accelerate Diagnostics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technologyhas an expected long-term adjusted earnings growth of almost 24%. The stock added roughly 43.8% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 81.4%.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock added roughly 9.8% over the last three months.
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...
Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Bruker Grows on NMR & Nano Businesses amid Several Odds
On Jun 6, we issued an updated research report on Billerica, MA-based Bruker Corporation (BRKR - Free Report) , a manufacturer of proprietary life science and materials research systems.
For quite sometime, Bruker has been witnessing growth in its Nano Surfaces business on restructuring and cost reduction actions. The portfolio also got a boost from the acquisition of Hysitron nano indenting products in the beginning of 2017. Additionally, the company gained traction in the semiconductor metrology markets and in certain industrial and applied end-market segments.
We are encouraged by Bruker’s latest product developmental activities under the Nuclear Magnetic Resonance (NMR) spectroscopy business. The company’s latest line of launches includes the AVANCE NEO platform, a next-generation NMR console and S8 TIGER Series 2 spectrometer. Management has also claimed to have made technical and quality progress with its high temperature superconducting (HTS) tapes. Currently, management expects HTS to boost its ultra-high field 1.2 gigahertz NMR business in 2018 and beyond. The market is also upbeat about Bruker’s new revolutionary approach for the analysis of microorganisms – MALDI Biotyper.
Over the recent past, Bruker has planned strategies to improve its financial performance. These initiatives include the divestiture of certain non-core businesses, outsourcing of various manufacturing activities and transferring or ceasing of operations at certain facilities. Meanwhile, the company’s raised revenue guidance raises optimism.
On the flip side, over the last three months, the company is trading below the Zacks categorized Instruments - Scientific industry. During this period, the stock has generated a return of 17.0%, below the 18.2% gain of the broader industry. We believe the underperformance is due to Bruker’s weak organic revenue performance.
Bruker conducts 80% of its business in international markets. As a result, adverse currency fluctuations continue to result in losses at the company. In 2017, changes in foreign currency rates are expected to have an adverse impact of 2.5% on revenues. In addition, currency fluctuations could make the price of Bruker’s products less competitive than that of its principal competitors' offerings. Moreover, headwinds such as unfavorable economic conditions and competitive threats continue to raise concerns.
Zacks Rank & Key Picks
Bruker currently carries Zacks Rank #3 (Hold). A few better-ranked medical stocks are Align Technology, Inc. (ALGN - Free Report) , Inogen, Inc. (INGN - Free Report) and Accelerate Diagnostics, Inc. (AXDX - Free Report) . Notably, Align Technologyand Inogen sport a Zacks Rank #1 (Strong Buy), while Accelerate Diagnostics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technologyhas an expected long-term adjusted earnings growth of almost 24%. The stock added roughly 43.8% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 81.4%.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock added roughly 9.8% over the last three months.
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...
Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>